Hanzel, Jurij http://orcid.org/0000-0003-3158-8014
Ma, Christopher http://orcid.org/0000-0002-4698-9948
Casteele, Niels Vande http://orcid.org/0000-0003-0854-0274
Khanna, Reena http://orcid.org/0000-0002-7493-2033
Jairath, Vipul http://orcid.org/0000-0003-1590-0338
Feagan, Brian G. http://orcid.org/0000-0002-6914-3822
Article History
First Online: 5 January 2021
Change Date: 28 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40265-021-01596-w
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: JH has received speaker’s fees from Biogen, Janssen, and Takeda. CM has received consulting fees from AbbVie, AVIR Pharma Inc, Janssen, Takeda, Pfizer, Roche, and Alimentiv (formerly Robarts Clinical Trials Inc.); speaker's fees from AbbVie, Janssen, Takeda, and Pfizer; and research support from the Canadian IBD Research Consortium and Pfizer. NVC has received research grants from R-Biopharm; grants and personal fees from Takeda and UCB; and personal fees from Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.), Celltrion, and Prometheus. These activities were all outside of the submitted work. RK has received consulting fees from AbbVie, Janssen, Takeda, Roche, Pendopharm, Lilly, Encycle, Shire, Alimentiv (formerly Robarts Clinical Trials Inc.), Pfizer, Inomar, and Merck. VJ has received consulting fees from AbbVie, Eli Lilly, GlaxoSmithKline, Arena Pharmaceuticals, Genetech, Pendopharm, Sandoz, Merck, Takeda, Janssen, Alimentiv (formerly Robarts Clinical Trials Inc.), Topivert, and Celltrion and speaker’s fees from Takeda, Janssen, Shire, Ferring, AbbVie, and Pfizer. BGF has received grant/research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc./Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, and UCB; consulting fees from Abbott/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, AstraZeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer Ingelheim, Bristol Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., and Zyngenia; speakers bureau fees from Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; is a scientific advisory board member for Abbott/AbbVie, Allergan, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestle, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is the Senior Scientific Officer of Alimentiv Inc. (formerly Robarts Clinical Trials Inc.).
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the drafting of the work or revising it critically for important intellectual content.